Stay updated with breaking news from Daniel Petrylak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.
Daniel Petrylak, MD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.
Daniel Petrylak, MD, discusses emerging therapeutic targets showing early potential in metastatic urothelial cancer.
Clinicians now have a third recommended radiotracer option for use in PET PSMA scans to determine treatment eligibility. ASCO has added another radiotracer to its recommended options for use in PSMA PET scans to determine 177lutetium-PSMA-617 treatment eligibility.
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors harboring